Arcus Biosciences, Inc. (RCUS) Stock
5 of the hedge funds AlphaScala tracks reported RCUS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $96.65M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own RCUS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.14M | $96.65M | +136% |
| Marshall Wace | 1.95M | $59.97M | -48% |
| Millennium Management Israel Englander | 133K | $4.10M | NEW |
| D.E. Shaw David Shaw | 96K | $2.97M | -63% |
| Blackstone | 18K | $546.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Arcus Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 26 | Azoy Alexander | Chief Accounting Officer | SELL | 2.8K | $85K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →RCUS price chart
Powered by TradingViewWhat does Arcus Biosciences, Inc. do?
Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.